

The cost of treating community-acquired pneumonia

Clinical Therapeutics

20, 820-837

DOI: [10.1016/s0149-2918\(98\)80144-6](https://doi.org/10.1016/s0149-2918(98)80144-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Community-acquired pneumonia. Disease-a-Month, 1998, 44, 613-675.	0.4	22
3	Secondary data bases and their use in outcomes research: a review of the area resource file and the Healthcare Cost and Utilization Project. Journal of Medical Systems, 1999, 23, 175-181.	2.2	36
4	Management of Community-Acquired Pneumonia. Disease Management and Health Outcomes, 1999, 6, 225-239.	0.3	4
5	A Critical Pathway for the Treatment of Community-Acquired Pneumonia. Drugs, 1999, 58, 273-275.	4.9	3
6	Treatment cost of acute exacerbations of chronic bronchitis. Clinical Therapeutics, 1999, 21, 576-591.	1.1	138
7	STRATEGIES FOR EARLY DISCHARGE OF THE HOSPITALIZED PATIENT WITH COMMUNITY-ACQUIRED PNEUMONIA. Clinics in Chest Medicine, 1999, 20, 599-605.	0.8	23
8	USE OF PROGNOSTIC SCORING AND OUTCOME ASSESSMENT TOOLS IN THE ADMISSION DECISION FOR COMMUNITY-ACQUIRED PNEUMONIA. Clinics in Chest Medicine, 1999, 20, 521-529.	0.8	20
9	Implementation of Admission Decision Support for Community-Acquired Pneumonia. Chest, 2000, 117, 1368-1377.	0.4	70
10	Care-seeking pattern and outcome of hospitalized pneumonia patients who are socioeconomically disadvantaged. Research in the Sociology of Health Care, 0, , 97-120.	0.1	0
11	A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2000, 283, 749.	3.8	615
12	Newer Fluoroquinolones and the Management of Respiratory Tract Infections. Clinical Infectious Diseases, 2000, 31, S15-S15.	2.9	1
13	Clarithromycin in the management of community-acquired pneumonia. Clinical Therapeutics, 2000, 22, 281-294.	1.1	23
14	Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clinical Therapeutics, 2000, 22, 872-878.	1.1	53
15	Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clinical Therapeutics, 2000, 22, 250-264.	1.1	43
16	Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Respiratory Medicine, 2000, 94, 97-105.	1.3	49
17	Community-Acquired Pneumonia in the Elderly. Drugs and Aging, 2000, 17, 93-105.	1.3	17
18	Length of hospitalization in elderly patients with community-acquired pneumonia. Aging Clinical and Experimental Research, 2000, 12, 35-41.	1.4	18
19	Community-Acquired Pneumonia in the Elderly. Clinical Infectious Diseases, 2000, 31, 1066-1078.	2.9	281

#	ARTICLE	IF	CITATIONS
20	Efficacy, Onset of Action and Tolerability of Moxifloxacin in Patients with Community-Acquired Pneumonia. <i>Clinical Drug Investigation</i> , 2001, 21, 801-811.	1.1	16
21	Community-Acquired Pneumonia and its Management. <i>Disease Management and Health Outcomes</i> , 2001, 9, 43-64.	0.3	4
22	Guidelines for the Management of Adults with Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1730-1754.	2.5	2,041
23	Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. <i>American Journal of Medicine</i> , 2001, 110, 306-309.	0.6	62
24	The benefits of, controversies surrounding, and professional recommendations for routine PSA testing: what do men believe?. <i>American Journal of Medicine</i> , 2001, 110, 309-313.	0.6	3
25	Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. <i>American Journal of Medicine</i> , 2001, 110, 451-457.	0.6	193
26	Critical evaluation of guidelines for the treatment of lower respiratory tract bacterial infections. <i>Respiratory Medicine</i> , 2001, 95, 95-108.	1.3	5
27	HOW SHOULD WE MAKE THE ADMISSION DECISION IN COMMUNITY-ACQUIRED PNEUMONIA?. <i>Medical Clinics of North America</i> , 2001, 85, 1397-1411.	1.1	18
28	Processes of Care, Illness Severity, and Outcomes in the Management of Community-Acquired Pneumonia at Academic Hospitals. <i>Archives of Internal Medicine</i> , 2001, 161, 2099.	4.3	100
29	Initial risk class and length of hospital stay in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2001, 18, 151-156.	3.1	56
30	Imaging of pneumonia: trends and algorithms. <i>European Respiratory Journal</i> , 2001, 18, 196-208.	3.1	221
31	Epidemiologic trends in the hospitalization of elderly Medicare patients for pneumonia, 1991-1998. <i>American Journal of Public Health</i> , 2001, 91, 1121-1123.	1.5	85
32	A Controlled Trial of a Critical Pathway for Treating Community-Acquired Pneumonia: The CAPITAL Study. <i>Pharmacotherapy</i> , 2001, 21, 89S-94S.	1.2	12
33	The Etiology of Community-Acquired Pneumonia at an Urban Public Hospital: Influence of Human Immunodeficiency Virus Infection and Initial Severity of Illness. <i>Journal of Infectious Diseases</i> , 2001, 184, 268-277.	1.9	96
34	Economic Burden of Pneumonia in an Employed Population. <i>Archives of Internal Medicine</i> , 2001, 161, 2725.	4.3	34
35	Cost-effectiveness of Gatifloxacin vs Ceftriaxone With a Macrolide for the Treatment of Community-Acquired Pneumonia. <i>Chest</i> , 2001, 119, 1439-1448.	0.4	80
36	Clinical Perspectives on New Antimicrobials: Focus on Fluoroquinolones. <i>Clinical Infectious Diseases</i> , 2001, 32, S64-S71.	2.9	22
37	Evaluation of the Clinical Microbiology Profile of Moxifloxacin. <i>Clinical Infectious Diseases</i> , 2001, 32, S51-S63.	2.9	46

#	ARTICLE	IF	CITATIONS
38	In Vivo Veritas: In Vitro Macrolide Resistance in Systemic Streptococcus pneumoniae Infections Does Result in Clinical Failure. <i>Clinical Infectious Diseases</i> , 2002, 35, 565-569.	2.9	55
39	Patient and Hospital Characteristics Associated With Recommended Processes of Care for Elderly Patients Hospitalized With Pneumonia. <i>Archives of Internal Medicine</i> , 2002, 162, 827.	4.3	65
40	Clinical Experience With Newer Quinolones for Community-Acquired Pneumonia. <i>Infectious Diseases in Clinical Practice</i> , 2002, , 527-533.	0.1	0
41	Economic Burden of Respiratory Infections in an Employed Population. <i>Chest</i> , 2002, 122, 603-611.	0.4	58
42	Carbapenems in the Treatment of Severe Community-Acquired Pneumonia in Hospitalized Elderly Patients: A Comparative Study Against Standard Therapy. <i>Journal of Chemotherapy</i> , 2002, 14, 609-617.	0.7	31
43	Management of Patients with Community-acquired Pneumonia Treated in Hospital in Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 887-892.	1.5	27
44	Tumor Necrosis Factor- α Converting Enzyme: Its Role in Community-Acquired Pneumonia. <i>Journal of Infectious Diseases</i> , 2002, 186, 1790-1796.	1.9	23
45	Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 61-70.	1.3	42
46	The Community-Acquired Pneumonia Symptom Questionnaire. <i>Chest</i> , 2002, 122, 920-929.	0.4	135
47	Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from a South American Working Group (ConsenSur). <i>Journal of Chemotherapy</i> , 2002, 14, 1-24.	0.7	9
48	Management of Community-Acquired Pneumonia. <i>New England Journal of Medicine</i> , 2002, 347, 2039-2045.	13.9	183
49	Guidelines for the management of Community-Acquired Pneumonia in Saudi Arabia: a model for the Middle East region. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 1-12.	1.1	105
50	A Critical Review of the Fluoroquinolones. <i>Drugs</i> , 2002, 62, 13-59.	4.9	303
51	Comparative Tolerability of Intravenous Erythromycin and Clarithromycin in Hospitalised Patients with Community-Acquired Pneumonia. <i>Clinical Drug Investigation</i> , 2002, 22, 393-398.	1.1	5
52	Hospitalized Community-acquired Pneumonia in the Elderly. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 766-772.	2.5	537
53	Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance. <i>Pharmacoeconomics</i> , 2002, 20, 513-528.	1.7	28
54	The evolution and role of macrolides in infectious diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1131-1151.	0.9	33
55	Cephalosporin-resistant pneumococcal pneumonia: does it, affect outcome?. <i>Respiratory Medicine</i> , 2002, 96, 805-811.	1.3	11

#	ARTICLE	IF	CITATIONS
56	Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 301-311.	0.8	62
57	Clinical Features and Outcomes of Community-Acquired Pneumonia. , 2002, , 29-34.		0
58	IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: Focus on gatifloxacin. <i>Advances in Therapy</i> , 2002, 19, 229-242.	1.3	4
60	Impact of Atypical Coverage for Patients with Community-Acquired Pneumonia Managed on the Medical Ward: Results from the United States Community-Acquired Pneumonia Project. <i>Pharmacotherapy</i> , 2003, 23, 1167-1174.	1.2	23
61	Cost analysis of pneumonia treatment in the Philippines. <i>International Journal of Health Planning and Management</i> , 2003, 18, 221-231.	0.7	3
62	Determinants for hospitalization in " low-risk" community acquired pneumonia. <i>BMC Infectious Diseases</i> , 2003, 3, 11.	1.3	33
63	Community-acquired pneumonia in elderly patients. <i>Clinics in Geriatric Medicine</i> , 2003, 19, 101-120.	1.0	36
64	Community-acquired pneumonia in the emergency department. <i>Emergency Medicine Clinics of North America</i> , 2003, 21, 395-420.	0.5	21
65	Valoraci3n de la gravedad y estimaci3n de los recursos sanitarios en los pacientes ingresados por neumon3a adquirida en la comunidad. <i>Revista De Calidad Asistencial: 3rgano De La Sociedad Espa3ola De Calidad Asistencial</i> , 2003, 18, 27-32.	0.6	0
66	Community-acquired pneumonia in the elderly. <i>Critical Care Clinics</i> , 2003, 19, 729-748.	1.0	37
67	Community-acquired pneumonia. <i>Lancet, The</i> , 2003, 362, 1991-2001.	6.3	435
68	Factors associated with hospitalization costs for patients with community acquired pneumonia. <i>Clinical Therapeutics</i> , 2003, 25, 593-610.	1.1	22
69	Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. <i>Lancet Infectious Diseases, The</i> , 2003, 3, 476-488.	4.6	51
70	Management of respiratory infections in the elderly. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 505-516.	2.0	10
71	The Cost of Treating Pneumonia in the Nursing Home Setting. <i>Journal of the American Medical Directors Association</i> , 2003, 4, 81-89.	1.2	17
72	Lower Respiratory Tract Infections. <i>Pharmacoeconomics</i> , 2003, 21, 749-759.	1.7	9
73	Local Impairment of Anti-Neutrophil Elastase Capacity in Community-Acquired Pneumonia. <i>Journal of Infectious Diseases</i> , 2003, 188, 769-776.	1.9	39
74	Factors Associated with Death among Adults <55 Years of Age Hospitalized for Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2003, 36, 413-421.	2.9	41

#	ARTICLE	IF	CITATIONS
75	Duration of length of stay in pneumonia: influence of clinical factors and hospital type. <i>European Respiratory Journal</i> , 2003, 22, 643-648.	3.1	56
76	Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1839-1846.	0.9	11
77	Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1269-1282.	1.3	17
78	Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2003, 21, 135-143.	3.1	88
79	Aspiration Pneumonia and Dysphagia in the Elderly. <i>Chest</i> , 2003, 124, 328-336.	0.4	741
80	The Contribution of Blood Cultures to the Clinical Management of Adult Patients Admitted to the Hospital With Community-Acquired Pneumonia. <i>Chest</i> , 2003, 123, 1142-1150.	0.4	216
81	Hospitalization for Community-Acquired Pneumonia. <i>Chest</i> , 2003, 124, 121-124.	0.4	102
82	What Is the Prognosis for Using the Pneumonia Severity Index To Make Site-of-Care Decisions In Community-Acquired Pneumonia?. <i>Chest</i> , 2003, 124, 2051-2053.	0.4	14
83	Cost and Incidence of Social Comorbidities in Low-Risk Patients With Community-Acquired Pneumonia Admitted to a Public Hospital. <i>Chest</i> , 2003, 124, 2148-2155.	0.4	89
85	Shoot, Ready, Aim: Pneumonia Care Quality and Costs in a Community Hospital. <i>American Journal of Medical Quality</i> , 2003, 18, 214-219.	0.2	2
86	Early Administration of Antibiotics Does Not Shorten Time to Clinical Stability in Patients With Moderate-to-Severe Community-Acquired Pneumonia *. <i>Chest</i> , 2003, 124, 1798-1804.	0.4	87
87	Variation in management of community-acquired pneumonia requiring admission to Alberta, Canada hospitals. <i>Epidemiology and Infection</i> , 2003, 130, 41-51.	1.0	37
88	Azithromycin Monotherapy for Patients Hospitalized With Community-Acquired Pneumonia. <i>Archives of Internal Medicine</i> , 2003, 163, 1718.	4.3	25
90	Current and future management of pneumonia. , 2003, , 363-402.		1
91	The Use of Clinical Practise Guidelines for Community-Acquired Pneumonia in Hospitals in Atlantic Canada. <i>Canadian Respiratory Journal</i> , 2004, 11, 301-303.	0.8	2
92	Inpatient Care of Community-Acquired Pneumonia: The Effect of Antimicrobial Guidelines on Clinical Outcomes and Drug Costs in Canadian Teaching Hospitals. <i>Canadian Respiratory Journal</i> , 2004, 11, 131-137.	0.8	17
93	Predicting Bacteremia in Patients with Community-Acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 342-347.	2.5	193
94	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. <i>Current Medical Research and Opinion</i> , 2004, 20, 739-747.	0.9	25

#	ARTICLE	IF	CITATIONS
95	Reaching Stability in Community-Acquired Pneumonia: The Effects of the Severity of Disease, Treatment, and the Characteristics of Patients. <i>Clinical Infectious Diseases</i> , 2004, 39, 1783-1790.	2.9	128
96	Development and validation of a short questionnaire in community acquired pneumonia. <i>Thorax</i> , 2004, 59, 591-595.	2.7	30
98	Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. <i>Thorax</i> , 2004, 59, 960-965.	2.7	256
99	Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. <i>European Respiratory Journal</i> , 2004, 24, 644-648.	3.1	18
101	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. <i>Current Medical Research and Opinion</i> , 2004, 20, 749-756.	0.9	15
102	Antibiotic Use-Changing Paradigms. <i>Infectious Diseases in Clinical Practice</i> , 2004, 12, S4-S7.	0.1	0
104	Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections. <i>International Journal of Clinical Practice</i> , 2004, 58, 769-776.	0.8	4
105	Outcomes and Costs Among Seniors Requiring Hospitalization for Community-Acquired Pneumonia in Alberta. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 31-38.	1.3	46
106	Antibacterial Resistance of Community-Acquired Respiratory Tract Pathogens Recovered from Patients in Germany and Activity of the Ketolide Telithromycin: Results from the PROTEKT Surveillance Study (1999-2000). <i>Chemotherapy</i> , 2004, 50, 143-151.	0.8	15
108	CAPNETZ?Community-Acquired Pneumonia Competence Network. <i>Infection</i> , 2004, 32, 234-8.	2.3	87
109	Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. <i>Journal of Infection</i> , 2004, 49, 115-125.	1.7	18
111	<i>Streptococcus pneumoniae</i> and community-acquired pneumonia: A cause for concern. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 39-50.	1.7	52
112	Review of treatment guidelines for community-acquired pneumonia. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 51-57.	1.7	21
113	Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. <i>Current Medical Research and Opinion</i> , 2004, 20, 969-980.	0.9	14
114	Cost of Stress Urinary Incontinence. <i>Pharmacoeconomics</i> , 2004, 22, 95-105.	1.7	44
115	Economic Aspects of Pneumococcal Pneumonia. <i>Pharmacoeconomics</i> , 2004, 22, 719-740.	1.7	35
116	Resource Use and Cost of Care for Patients Hospitalised with Community Acquired Pneumonia. <i>Pharmacoeconomics</i> , 2004, 22, 751-757.	1.7	45
117	A population-based study of the costs of care for community-acquired pneumonia. <i>European Respiratory Journal</i> , 2004, 23, 610-616.	3.1	71

#	ARTICLE	IF	CITATIONS
119	Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2004, , .	1.1	0
123	Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 533-546.	1.1	25
124	Once-Daily Moxifloxacin Therapy for???Community-Acquired Pneumonia in???General Practice. <i>Clinical Drug Investigation</i> , 2004, 24, 441-448.	1.1	13
125	Drug Treatment of Pneumococcal Pneumonia in the Elderly. <i>Drugs and Aging</i> , 2004, 21, 851-864.	1.3	23
126	Guidelines for Community-Acquired Pneumonia. <i>Treatments in Respiratory Medicine</i> , 2004, 3, 67-77.	1.4	21
127	Epidemiology and etiology of community-acquired pneumonia. <i>Infectious Disease Clinics of North America</i> , 2004, 18, 761-776.	1.9	75
128	Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2004, 15, 28-34.	1.0	15
129	Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. <i>American Journal of Medicine</i> , 2004, 116, 385-393.	0.6	22
130	Limited Impact of a Multicenter Intervention To Improve the Quality and Efficiency of Pneumonia Care. <i>Chest</i> , 2004, 126, 100-107.	0.4	45
131	Community-acquired pneumoniaâ€”optimizing antibiotic usage. <i>Current Opinion in Pulmonary Medicine</i> , 2004, 10, S4-S8.	1.2	2
132	Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. <i>Critical Care Medicine</i> , 2004, 32, 2398-2402.	0.4	49
133	A Comparison of the National Ambulatory Medical Care Survey (NAMCS) Measurement Approach With Direct Observation of Outpatient Visits. <i>Medical Care</i> , 2004, 42, 276-280.	1.1	156
134	Hospitalist Management of Community-Acquired Pneumonia. <i>Infectious Diseases in Clinical Practice</i> , 2004, 12, S17-S22.	0.1	0
135	Community-acquired Pneumonia. <i>Critical Care Nursing Quarterly</i> , 2004, 27, 231-240.	0.4	6
136	Guidelines for community-acquired pneumonia in the ICU. <i>Current Opinion in Critical Care</i> , 2004, 10, 59-64.	1.6	17
137	Importance of severity of illness assessment in management of lower respiratory infections. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 121-125.	1.3	15
138	Treatment Costs of Community-Acquired Pneumonia in an Employed Population. <i>Chest</i> , 2004, 125, 2140-2145.	0.4	113
139	Community Acquired Pneumonia in Internal Medicine: A One-Year Retrospective Study Based on Pneumonia Severity Index. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 575-586.	1.0	12

#	ARTICLE	IF	CITATIONS
140	Single-Dose Azithromycin Microspheres vs Clarithromycin Extended Release for the Treatment of Mild-to-Moderate Community-Acquired Pneumonia in Adults. <i>Chest</i> , 2005, 128, 2230-2237.	0.4	69
141	Cost Analyses of Community-Acquired Pneumonia From the Hospital Perspective. <i>Chest</i> , 2005, 128, 2238-2246.	0.4	68
142	What Have We Learned About How to Measure Quality of Care for Patients with Community-acquired Pneumonia?. <i>Respiratory Care Clinics of North America</i> , 2005, 11, 87-98.	0.5	6
143	Are Blood Cultures Necessary in Community-Acquired Pneumonia?. <i>Clinical Pulmonary Medicine</i> , 2005, 12, 146-152.	0.3	3
144	Management of Community-Acquired Pneumonia in the Home. <i>Chest</i> , 2005, 127, 1752-1763.	0.4	33
145	Do Guidelines Guide Pneumonia Practice? A Systematic Review of Interventions and Barriers to Best Practice in the Management of Community-acquired Pneumonia. <i>Respiratory Care Clinics of North America</i> , 2005, 11, 1-13.	0.5	44
146	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 357-373.	0.2	0
147	Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. <i>Clinical Microbiology and Infection</i> , 2005, 11, 788-800.	2.8	77
148	Predicting dire outcomes of patients with community acquired pneumonia. <i>Journal of Biomedical Informatics</i> , 2005, 38, 347-366.	2.5	50
150	Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 377-383.	1.3	50
151	Determinants of Hospital Length of Stay among Patients with Pneumonia Admitted to a Large Canadian Hospital from 1991 to 2001. <i>Canadian Respiratory Journal</i> , 2005, 12, 365-370.	0.8	9
152	Pneumonia Guidelines in Practice. , 2005, , 37-66.		0
153	Challenges in the Management of Community-Acquired Pneumonia: The Role of Quinolones and Moxifloxacin. <i>Clinical Infectious Diseases</i> , 2005, 41, S158-S166.	2.9	12
154	Costs and Outcomes of Extended-Release vs. Immediate-Release Clarithromycin for Lower Respiratory Tract Infections. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 217-223.	0.7	1
155	Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 1697-1705.	2.9	92
156	Breathing and Swallowing Dynamics Across the Adult Lifespan. <i>JAMA Otolaryngology</i> , 2005, 131, 762.	1.5	229
157	Pneumonia in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2760.	3.8	17
158	Novel, Single-Dose Microsphere Formulation of Azithromycin versus 7-Day Levofloxacin Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4035-4041.	1.4	67

#	ARTICLE	IF	CITATIONS
159	Getting Physicians to Make "The Switch": The Role of Clinical Guidelines in the Management of Community-Acquired Pneumonia. <i>American Journal of Medical Quality</i> , 2005, 20, 15-21.	0.2	15
160	Accuracy of Administrative Data for Identifying Patients With Pneumonia. <i>American Journal of Medical Quality</i> , 2005, 20, 319-328.	0.2	170
161	Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine. <i>FASEB Journal</i> , 2005, 19, 1209-1215.	0.2	10
162	Clinical predictors of bioterrorism-related inhalational anthrax. <i>Lancet, The</i> , 2005, 365, 214.	6.3	2
164	Project Protect: Pneumococcal vaccination in Washington State nursing homes* *A collaboration between Qualis Health, Washington State Department of Health, and the Immunization Coalition of Washington.. <i>Journal of the American Medical Directors Association</i> , 2005, 6, 91-96.	1.2	8
165	Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 791-805.	1.5	39
166	Influenza and Pneumonia in Pregnancy. <i>Clinics in Perinatology</i> , 2005, 32, 727-738.	0.8	62
167	An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. <i>Current Medical Research and Opinion</i> , 2005, 21, 261-270.	0.9	0
168	The burden of pneumonia in children in the developed world. <i>Paediatric Respiratory Reviews</i> , 2005, 6, 76-82.	1.2	71
169	Efficacy and Tolerability of Sequential Intravenous/Oral Moxifloxacin Therapy in Pneumonia. <i>Clinical Drug Investigation</i> , 2005, 25, 691-700.	1.1	9
170	Short-Course Antimicrobial Therapy for Community-Acquired Pneumonia. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 231-239.	1.4	8
171	Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 353-360.	2.0	3
172	Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia. <i>Annals of Internal Medicine</i> , 2005, 142, 165.	2.0	211
174	Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and Safety of Moxifloxacin Therapy versus That of Levofloxacin Therapy. <i>Clinical Infectious Diseases</i> , 2006, 42, 73-81.	2.9	81
175	Chest Pain: A Clinical Assessment. <i>Radiologic Clinics of North America</i> , 2006, 44, 165-179.	0.9	18
176	Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, S115-S127.	1.1	13
177	Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review. <i>International Journal of Infectious Diseases</i> , 2006, 10, 136-147.	1.5	8
178	Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired Pneumonia. <i>American Journal of Medicine</i> , 2006, 119, 865-871.	0.6	124

#	ARTICLE	IF	CITATIONS
179	Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant <i>Staphylococcus aureus</i> . <i>Clinical Therapeutics</i> , 2006, 28, 1184-1198.	1.1	38
180	Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 267-275.	0.8	9
181	Approaches to treatment of community-acquired pneumonia in the Emergency Department and the appropriate role of fluoroquinolones. <i>Journal of Emergency Medicine</i> , 2006, 30, 377-387.	0.3	12
182	Conditional expression of interferon- β to enhance host responses to pulmonary bacterial infection. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 251-257.	1.1	7
183	Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. <i>Respiratory Medicine</i> , 2006, 100, 2129-2136.	1.3	41
184	Manejo de la neumonía comunitaria del adulto en el Servicio de Salud Viña del Mar-Quillota. Abril - Septiembre de 2003. <i>Revista Chilena De Enfermedades Respiratorias</i> , 2006, 22, 13.	0.1	1
186	Discharge Delay in Patients with Community-Acquired Pneumonia Managed on a Critical Pathway. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2006, 17, 109-113.	0.7	8
187	Pneumonia Severity Index in the Immunocompromised. <i>Canadian Respiratory Journal</i> , 2006, 13, 89-93.	0.8	33
188	Reasons for Coming to Hospital after Treatment for Community-Acquired Pneumonia on an Ambulatory Basis. <i>Canadian Respiratory Journal</i> , 2006, 13, 139-143.	0.8	1
189	Antimicrobial treatment of community-acquired pneumonia in the elderly. <i>Aging Health</i> , 2006, 2, 999-1011.	0.3	4
192	Resource Utilization of Adults Admitted to a Large Urban Hospital With Community-Acquired Pneumonia Caused by <i>Streptococcus pneumoniae</i> . <i>Chest</i> , 2006, 130, 807-814.	0.4	29
193	Snapshots for November 2006. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 341-344.	0.1	0
194	The role of new therapies for severe community-acquired pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 557-564.	1.3	8
195	Impact of antibiotic restrictions: the physician's perspective. <i>Clinical Microbiology and Infection</i> , 2006, 12, 3-9.	2.8	11
196	Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. <i>Journal of Internal Medicine</i> , 2006, 259, 410-417.	2.7	129
197	Coordination of Swallowing and Respiration in Normal Sequential Cup Swallows. <i>Laryngoscope</i> , 2006, 116, 1489-1493.	1.1	83
198	The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. <i>Journal of Infection</i> , 2006, 53, 166-174.	1.7	179
199	Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2006, 25, 159-166.	1.3	39

#	ARTICLE	IF	CITATIONS
200	Factors influencing the costs of emergency medical admissions to an Irish teaching hospital. <i>European Journal of Health Economics</i> , 2006, 7, 123-128.	1.4	14
201	“Above or below?” <i>Journal of Hospital Medicine</i> , 2006, 1, 36-41.	0.7	1
203	Improved Clinical Outcomes With Utilization of a Community-Acquired Pneumonia Guideline. <i>Chest</i> , 2006, 130, 794-799.	0.4	175
204	Adverse Events in Patients With Community-Acquired Pneumonia at an Academic Tertiary Emergency Department. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 350-359.	0.1	5
205	Pneumonia in the Elderly. <i>Current Respiratory Medicine Reviews</i> , 2006, 2, 75-87.	0.1	1
206	Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. <i>European Respiratory Journal</i> , 2006, 27, 9-11.	3.1	61
207	Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2006, 28, 816-823.	3.1	57
208	Comparing Gatifloxacin and Clarithromycin in Pneumonia Symptom Resolution and Process of Care. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1164-1169.	1.4	12
209	Hospitalization Trends for Pneumonia Among Older Persons. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2137.	3.8	0
210	Clinical implications of macrolide resistance in community-acquired respiratory tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 973-980.	2.0	18
211	Unplayed Melodies: Javanese Gamelan and the Genesis of Music Theory: Unplayed Melodies: Javanese Gamelan and the Genesis of Music Theory. <i>Music Theory Spectrum</i> , 2007, 29, 247-253.	0.7	0
212	Recent Advances in Community-Acquired Pneumonia. <i>Chest</i> , 2007, 131, 1205-1215.	0.4	71
213	Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. <i>Thorax</i> , 2007, 62, 348-353.	2.7	166
214	Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 112-120.	1.3	66
215	Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 977-989.	1.3	22
216	The Impact of Standardized Order Sets and Intensive Clinical Case Management on Outcomes in Community-Acquired Pneumonia. <i>Archives of Internal Medicine</i> , 2007, 167, 1664.	4.3	44
217	How long should we treat community-acquired pneumonia?. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 177-181.	1.3	19
218	Hyponatremia in Community-Acquired Pneumonia. <i>American Journal of Nephrology</i> , 2007, 27, 184-190.	1.4	139

#	ARTICLE	IF	CITATIONS
219	Pneumonia in the Older Patient. <i>Clinics in Chest Medicine</i> , 2007, 28, 751-771.	0.8	37
220	Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <i>Clinical Infectious Diseases</i> , 2007, 44, S27-S72.	2.9	5,203
221	Community-acquired pneumonia in the childhood: analysis of the diagnostic methods. <i>Brazilian Journal of Infectious Diseases</i> , 2007, 11, 246-248.	0.3	4
222	Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. <i>Respirology</i> , 2007, 12, 111-116.	1.3	41
223	A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. <i>Respirology</i> , 2007, 12, 754-758.	1.3	51
224	The value of prognostic indices for pneumonia. <i>Current Infectious Disease Reports</i> , 2008, 10, 215-222.	1.3	9
225	Objective Computer-Based Assessment of Valleculae Residue " Is It Useful?. <i>Dysphagia</i> , 2008, 23, 7-15.	1.0	32
226	Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2008, 8, 16.	0.8	106
227	Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia. <i>Annals of Emergency Medicine</i> , 2008, 52, 48-58.e2.	0.3	196
228	A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. <i>Current Medical Research and Opinion</i> , 2008, 24, 1279-1284.	0.9	13
229	Benefit-Risk Assessment of Telithromycin in the Treatment of Community-Acquired Pneumonia. <i>Drug Safety</i> , 2008, 31, 561-575.	1.4	13
230	Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia. <i>Drugs</i> , 2008, 68, 1841-1854.	4.9	132
231	Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia. <i>Drugs</i> , 2008, 68, 2469-2481.	4.9	70
233	Role of gemifloxacin in community-acquired pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 405-418.	2.0	3
234	A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. <i>Current Medical Research and Opinion</i> , 2008, 24, 737-751.	0.9	15
235	Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. <i>Drugs and Aging</i> , 2008, 25, 585-610.	1.3	23
236	C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired Pneumonia. <i>American Journal of Medicine</i> , 2008, 121, 219-225.	0.6	303
237	Efficacy of clinical guideline implementation to improve the appropriateness of chest physiotherapy prescription among inpatients with community-acquired pneumonia. <i>Respiratory Medicine</i> , 2008, 102, 1257-1263.	1.3	14

#	ARTICLE	IF	CITATIONS
238	Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: A retrospective claims database analysis. <i>Clinical Therapeutics</i> , 2008, 30, 358-371.	1.1	36
239	Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 59-64.	0.8	17
240	Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. <i>Current Medical Research and Opinion</i> , 2008, 24, 1601-1608.	0.9	666
241	Treatment of Oral and Pharyngeal Dysphagia. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2008, 19, 803-816.	0.7	70
242	Measuring Acceptable Treatment Failure Rates for Community-Acquired Pneumonia: Potential for Reducing Duration of Treatment and Antimicrobial Resistance. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 137-142.	1.0	10
243	Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. <i>Cmaj</i> , 2008, 179, 1269-1277.	0.9	75
244	A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. <i>Current Medical Research and Opinion</i> , 2008, 24, 895-906.	0.9	25
245	Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 267-283.	0.9	37
246	The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. <i>Critical Care</i> , 2008, 12, S5.	2.5	29
247	Position Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2008, 47, S249-S265.	2.9	58
248	Comparison of 2 Interventions for Liquid Aspiration on Pneumonia Incidence. <i>Annals of Internal Medicine</i> , 2008, 148, 509.	2.0	257
249	Determinants of hospital costs in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2008, 31, 1061-1067.	3.1	38
250	Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. <i>European Respiratory Journal</i> , 2008, 32, 139-146.	3.1	169
251	SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2008, 47, 375-384.	2.9	458
252	Significant publications on infectious diseases pharmacotherapy in 2007. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, e72-e79.	0.5	11
253	Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1945-1951.	1.4	23
254	Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. <i>European Respiratory Journal</i> , 2008, 31, 1068-1076.	3.1	28
255	Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1162-1168.	1.3	32

#	ARTICLE	IF	CITATIONS
256	Review: Novel targets in the management of pneumonia. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 387-400.	1.0	8
257	Diagnosing and treating CAP in immunocompetent adults. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2008, 21, 26-30.	0.1	2
258	Overview of Results From the Largest Clinical Trial for Dysphagia Treatment Efficacy. <i>Perspectives on Swallowing and Swallowing Disorders (Dysphagia)</i> , 2008, 17, 59-66.	0.2	3
259	Continuous Infusion of Time-dependent Antibiotics. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 167-172.	0.3	1
260	Association between Proton Pump Inhibitors and Respiratory Infections: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008, 22, 761-766.	1.8	70
261	Tigecycline in the Treatment of Community-Acquired Pneumonia. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2351.	0.1	0
262	Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. <i>Current Medical Research and Opinion</i> , 2009, 25, 2151-2157.	0.9	56
263	Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study. <i>Current Medical Research and Opinion</i> , 2009, 25, 859-868.		13
264	Community-Acquired Pneumonia: The U.S. Perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 179-188.	0.8	43
265	Impact of Guidelines on Outcome: The Evidence. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 172-178.	0.8	37
266	Guideline-Concordant Therapy and Reduced Mortality and Length of Stay in Adults With Community-Acquired Pneumonia. <i>Archives of Internal Medicine</i> , 2009, 169, 1525.	4.3	178
267	Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 127-135.	0.8	105
268	Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. <i>European Respiratory Journal</i> , 2009, 34, 1148-1158.	3.1	85
269	Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. <i>Archives of Internal Medicine</i> , 2009, 169, 1515.	4.3	106
270	Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission. <i>Clinical Infectious Diseases</i> , 2009, 48, 377-385.	2.9	154
271	Making sense of scoring systems in community acquired pneumonia. <i>Respirology</i> , 2009, 14, 327-335.	1.3	59
272	Potential for Cost-Savings in the Care of Hospitalized Low-Risk Community-Acquired Pneumonia Patients in China. <i>Value in Health</i> , 2009, 12, 40-46.	0.1	15
273	Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia. <i>Value in Health</i> , 2009, 12, 1135-1143.	0.1	6

#	ARTICLE	IF	CITATIONS
274	Aetiology of, and risk factors for, recurrent community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2009, 15, 1033-1038.	2.8	58
275	Diagnostic utility of CRP to neopterin ratio in patients with acute respiratory tract infections. <i>Journal of Infection</i> , 2009, 58, 123-130.	1.7	28
276	BTS guidelines for the management of community acquired pneumonia in adults: update 2009. <i>Thorax</i> , 2009, 64, iii1-iii55.	2.7	1,039
277	Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 69-81.	2.0	1
278	Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. <i>Current Medical Research and Opinion</i> , 2009, 25, 2447-2457.	0.9	9
279	Severe Community-Acquired Pneumonia. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 503-520.	1.9	65
280	Oropharyngeal Dysphagia Assessment and Treatment Efficacy: Setting the Record Straight (Response) <i>TJ ETQq0 0 0 rgBT /Overlock 10 T</i>	1.2	34
281	Healthcare Utilization in Community-Acquired Pneumonia Episodes of Care. <i>Medical Care</i> , 2009, 47, 1084-1090.	1.1	1
282	Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2009, 16, 243-251.	0.3	1
283	Procalcitonin Levels Predict Bacteremia in Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2010, 138, 121-129.	0.4	240
284	Correlates of Bacterial Pneumonia Hospitalizations in Elders, Texas Border. <i>Journal of Immigrant and Minority Health</i> , 2010, 12, 423-432.	0.8	3
285	Cethromycin: A Promising New Ketolide Antibiotic for Respiratory Infections. <i>Pharmacotherapy</i> , 2010, 30, 290-303.	1.2	34
286	Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. <i>BMC Pulmonary Medicine</i> , 2010, 10, 12.	0.8	22
287	Fluoroquinolones in the management of community-acquired pneumonia. <i>International Journal of Clinical Practice</i> , 2010, 64, 378-388.	0.8	25
288	Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 195-200.	0.7	31
289	Infections of the lower respiratory tract. , 2010, , 574-588.		0
290	NeumonÃa aguda adquirida en la comunidad en adultos: ActualizaciÃ³n de los lineamientos para el tratamiento antimicrobiano inicial basado en la evidencia local del Grupo de Trabajo de SudamÃ©rica (ConsenSur II). <i>Revista Chilena De Infectologia</i> , 0, 27, .	0.0	11
291	Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. <i>Current Medical Research and Opinion</i> , 2010, 26, 355-363.	0.9	3

#	ARTICLE	IF	CITATIONS
292	Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. <i>European Respiratory Journal</i> , 2010, 35, 858-864.	3.1	25
293	C-reactive protein for discriminating treatment failure from slow responding pneumonia. <i>European Journal of Internal Medicine</i> , 2010, 21, 548-552.	1.0	22
294	Statins in community acquired pneumonia: Evidence from experimental and clinical studies. <i>Respiratory Medicine</i> , 2010, 104, 1081-1091.	1.3	69
295	Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia. <i>American Journal of Medicine</i> , 2010, 123, S39-S46.	0.6	9
296	Community-acquired pneumonia in the elderly. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 47-62.	3.0	84
297	Fluoroquinolones in the management of community-acquired pneumonia in primary care. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1259-1271.	2.0	17
298	Community acquired bacterial pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 361-374.	0.9	35
299	Fluoroquinolones in Community-Acquired Pneumonia. <i>Drugs</i> , 2011, 71, 757-770.	4.9	14
300	Chest Radiography Today and Its Remaining Indications. <i>Medical Radiology</i> , 2011, , 3-26.	0.0	1
301	Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. <i>Respiratory Medicine</i> , 2011, 105, 1732-1738.	1.3	35
302	One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. <i>International Journal of Infectious Diseases</i> , 2011, 15, e382-e387.	1.5	37
303	The impact of the Brazil experience in Latin America. <i>Lancet, The</i> , 2011, 377, 1984-1986.	6.3	6
304	Glucocorticoid treatment in community-acquired pneumonia. <i>Lancet, The</i> , 2011, 377, 1982-1984.	6.3	15
305	How important is age in defining the prognosis of patients with community-acquired pneumonia?. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 142-147.	1.3	19
306	CURB-65 Pneumonia Severity Assessment Adapted for Electronic Decision Support. <i>Chest</i> , 2011, 140, 156-163.	0.4	64
307	Reported Pneumonia in Patients With COPD. <i>Chest</i> , 2011, 139, 505-512.	0.4	158
308	Compliance with the CURB-65 score and the consequences of non-implementation. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1697-1702.	0.6	6
309	Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. <i>The Cochrane Library</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
310	Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1852-1858.	2.8	46
312	Analysis of systemic corticosteroid usage and survival in patients requiring mechanical ventilation for severe community-acquired pneumonia. <i>Journal of Infection and Chemotherapy</i> , 2011, 17, 449-455.	0.8	14
313	Modern Management of Community-Acquired Pneumonia: Is It Cost-Effective and are Outcomes Acceptable?. <i>Current Infectious Disease Reports</i> , 2011, 13, 269-277.	1.3	7
315	Thirty-Day Readmission Rates for Medicare Beneficiaries by Race and Site of Care. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 675.	3.8	637
316	Group V Phospholipase A2 in Bone Marrow-derived Myeloid Cells and Bronchial Epithelial Cells Promotes Bacterial Clearance after <i>Escherichia coli</i> Pneumonia. <i>Journal of Biological Chemistry</i> , 2011, 286, 35650-35662.	1.6	22
317	Insufficient evidence to recommend routine adjunctive chest physiotherapy for adults with pneumonia. <i>Evidence-based Nursing</i> , 2011, 13, 73-74.	0.1	1
318	Management of community-acquired pneumonia: a review and update. <i>Therapeutic Advances in Respiratory Disease</i> , 2011, 5, 61-78.	1.0	48
319	Which Pneumonia Severity Scoring System is the Best?. <i>Current Respiratory Medicine Reviews</i> , 2011, 7, 232-245.	0.1	1
320	Changing needs of community-acquired pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, iii3-iii9.	1.3	47
321	Risk and Prognosis of Hospitalization for Pneumonia Among Individuals With and Without Functioning Renal Transplants in Denmark: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 679-686.	2.9	16
322	Community-Acquired Pneumonia Guidelines: A Global Perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 298-310.	0.8	38
323	Evaluation of the IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia. <i>Hospital Practice (1995)</i> , 2012, 40, 158-164.	0.5	6
324	Technology Implementation Impacting the Outcomes of Patients with CAP. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 292-297.	0.8	4
325	Radiologic Predictors of Hyponatremia in Children Hospitalized With Community-Acquired Pneumonia. <i>Pediatric Emergency Care</i> , 2012, 28, 764-766.	0.5	6
326	Clinical efficacy of cefixim compared to amoxicillin- clavulanate in community acquired pneumonia treatment. <i>African Journal of Pharmacy and Pharmacology</i> , 2012, 6, 3242-3245.	0.2	1
327	Incidence and Cost of Pneumonia in Medicare Beneficiaries. <i>Chest</i> , 2012, 142, 973-981.	0.4	94
328	Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2012, 142, 1193-1199.	0.4	56
329	BLUP(REMQL) estimation of a correlated random effects negative binomial hurdle model. <i>Health Services and Outcomes Research Methodology</i> , 2012, 12, 302-319.	0.8	4

#	ARTICLE	IF	CITATIONS
330	Risk of Death Associated With Use of PPIs in Three Cohorts of Institutionalized Older People in Finland. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 488.e9-488.e13.	1.2	27
331	The natural history of community-acquired pneumonia in COPD patients: A population database analysis. <i>Respiratory Medicine</i> , 2012, 106, 1124-1133.	1.3	155
332	The Effects of Incorporating a Pneumonia Severity Index into the Admission Protocol for Community-Acquired Pneumonia. <i>Journal of Emergency Medicine</i> , 2012, 42, 133-138.	0.3	14
333	Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain). <i>BMC Infectious Diseases</i> , 2012, 12, 283.	1.3	29
334	Clinical and Economic Burden of Community-Acquired Pneumonia in the Medicare Fee-for-Service Population. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2137-2143.	1.3	69
335	CURB-65 score predicted mortality in community-acquired pneumonia better than IDSA/ATS minor criteria in a low-mortality-rate setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 3281-3286.	1.3	12
336	Outcomes in elderly Danish citizens admitted with community-acquired pneumonia. Regional differences, in a public healthcare system. <i>Respiratory Medicine</i> , 2012, 106, 1778-1787.	1.3	34
337	Pneumonia in frail older patients: an up to date. <i>Internal and Emergency Medicine</i> , 2012, 7, 415-424.	1.0	30
338	Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults. <i>BMC Health Services Research</i> , 2012, 12, 379.	0.9	35
339	Tele-Dysphagia Management: An Opportunity for Prevention, Cost-Savings and Advanced Training. <i>International Journal of Telerehabilitation</i> , 2012, 4, 41-46.	0.7	20
340	Clinical features of spinal infection in individuals older than eighty years. <i>International Orthopaedics</i> , 2012, 36, 1229-1234.	0.9	14
341	Hospital Admission Decision for Patients With Community-Acquired Pneumonia: Variability Among Physicians in an Emergency Department. <i>Annals of Emergency Medicine</i> , 2012, 59, 35-41.	0.3	69
342	National Study of Antibiotic Use in Emergency Department Visits for Pneumonia, 1993 Through 2008. <i>Academic Emergency Medicine</i> , 2012, 19, 562-568.	0.8	17
343	Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 33-47.	1.3	43
344	Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. <i>American Journal of Emergency Medicine</i> , 2013, 31, 602-612.	0.7	35
345	Emergency Department and Inpatient Community-Acquired Pneumonia: Practical Decision Making and Management Issues. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 172-180.	0.6	0
346	Evaluation of hospital admission criteria for community acquired-pneumonia patients at a private hospital in UAE. <i>Journal of Pharmacy Research</i> , 2013, 7, 267-270.	0.4	1
349	Evaluation of diagnostic and prognostic value of high sensitivity C reactive protein (Hs-CRP) in community acquired pneumonia. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2013, 62, 301-304.	0.1	4

#	ARTICLE	IF	CITATIONS
350	Recomendaciones para el diagnóstico, tratamiento y prevención de la neumonía adquirida en la comunidad en adultos inmunocompetentes. <i>Infectio</i> , 2013, 17, 1-38.	0.4	26
351	Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission. <i>Journal of Critical Care</i> , 2013, 28, 284-290.	1.0	18
352	Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP. <i>BMC Infectious Diseases</i> , 2013, 13, 597.	1.3	9
353	PSI, CURB-65, SMART-COP or SCAP? And the winner is... SMART DOCTORS. <i>Revista Portuguesa De Pneumologia</i> , 2013, 19, 243-244.	0.7	7
354	Severe Community-Acquired Pneumonia. <i>Critical Care Clinics</i> , 2013, 29, 563-601.	1.0	67
355	Periodontal infections and community-acquired pneumonia: a case-control study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 27-32.	1.3	36
356	Community-Acquired Pneumonia Team Decreases Length of Stay in Hospitalized, Low-Risk Patients With Pneumonia. <i>Hospital Practice (1995)</i> , 2013, 41, 7-14.	0.5	11
357	Rates of Emergency Department Visits Due to Pneumonia in the United States, July 2006-June 2009. <i>Academic Emergency Medicine</i> , 2013, 20, 957-960.	0.8	40
358	Work-Related and Health Care Cost Burden of Community-Acquired Pneumonia in an Employed Population. <i>Journal of Occupational and Environmental Medicine</i> , 2013, 55, 1149-1156.	0.9	8
359	Patients hospitalized for community-acquired pneumonia present reduced functional performance. <i>Brazilian Journal of Physical Therapy</i> , 2013, 17, 351-358.	1.1	9
360	Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 83.	0.7	5
361	Epidemiology and Treatment Options for Select Community-Acquired and Nosocomial Antibiotic-Resistant Pathogens. , 2014, , 387-400.		1
362	Ceftaroline Fosamil for the Treatment of Community-Acquired Bacterial Pneumonia in Elderly Patients. <i>Hospital Practice (1995)</i> , 2014, 42, 109-115.	0.5	8
363	Management of community-acquired pneumonia in older adults. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 3-16.	1.1	68
365	Macrolides and Mortality in Critically Ill Patients With Community-Acquired Pneumonia. <i>Critical Care Medicine</i> , 2014, 42, 420-432.	0.4	154
366	Rates and Risk Factors for Recurrent Pneumonia in Patients Hospitalized With Community-Acquired Pneumonia: Population-Based Prospective Cohort Study With 5 Years of Follow-up. <i>Clinical Infectious Diseases</i> , 2014, 59, 74-80.	2.9	36
367	Validating hospital admission criteria for decision support in pneumonia. <i>BMC Pulmonary Medicine</i> , 2014, 14, 149.	0.8	14
368	Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 36.	0.8	26

#	ARTICLE	IF	CITATIONS
369	Studying the burden of community-acquired pneumonia in adults aged ≥50 years in primary health care: an observational study in rural Crete, Greece. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14017.	1.1	13
370	Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or Î²-Lactam + Macrolide Versus Î²-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients. <i>Medicine (United States)</i> , 2015, 94, e1662.	0.4	4
371	Acute Pneumonia. , 2015, , 823-846.e5.		10
372	The Irregular Diaphragmatic Pleural Interface. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 1147-1157.	0.8	1
373	Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study. <i>Infection</i> , 2015, 43, 671-680.	2.3	39
374	Community-Acquired Pneumonia in Older Adults. <i>Current Geriatrics Reports</i> , 2015, 4, 51-59.	1.1	4
375	Assessment of Time to Clinical Response, a Proxy for Discharge Readiness, among Hospitalized Patients with Community-Acquired Pneumonia Who Received either Ceftaroline Fosamil or Ceftriaxone in Two Phase III FOCUS Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1119-1126.	1.4	19
376	Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007â€“2011 Medical Expenditure Panel Survey. <i>Clinical Therapeutics</i> , 2015, 37, 1466-1476.e1.	1.1	29
377	Recurrent Pneumonia: A Review with Focus on Clinical Epidemiology and Modifiable Risk Factors in Elderly Patients. <i>Drugs and Aging</i> , 2015, 32, 13-19.	1.3	43
378	Effects of Deviceâ€“Facilitated Isometric Progressive Resistance Oropharyngeal Therapy on Swallowing and Healthâ€“Related Outcomes in Older Adults with Dysphagia. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 417-424.	1.3	64
379	Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis. <i>Annals of Family Medicine</i> , 2016, 14, 552-566.	0.9	65
380	Effectiveness of endoscopic cricopharyngeal myotomy in adults with neurological disease: systematic review. <i>Journal of Laryngology and Otology</i> , 2016, 130, 1077-1085.	0.4	5
381	CAPECO: Cost evaluation of community acquired pneumonia managed in primary care. <i>Vaccine</i> , 2016, 34, 2275-2280.	1.7	16
383	Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With Pneumonia. <i>Chest</i> , 2016, 149, 1509-1515.	0.4	57
384	Validation of modified early warning score using serum lactate level in community-acquired pneumonia patients. The National Early Warning Scoreâ€“Lactate score. <i>American Journal of Emergency Medicine</i> , 2016, 34, 536-541.	0.7	40
386	Pharmacotherapy for community-acquired pneumonia in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 957-964.	0.9	11
387	The Prevalence of Oropharyngeal Dysphagia in Danish Patients Hospitalised with Community-Acquired Pneumonia. <i>Dysphagia</i> , 2017, 32, 383-392.	1.0	23
388	Factors associated with 30-day mortality in elderly inpatients with community acquired pneumonia during 2 influenza seasons. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 450-455.	1.4	20

#	ARTICLE	IF	CITATIONS
389	Bacterial Pneumonia in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 689-713.	1.9	80
390	Treatment of Community-Acquired Pneumonia: A Case Report and Current Treatment Dilemmas. <i>Case Reports in Emergency Medicine</i> , 2017, 2017, 1-7.	0.1	3
391	South African guideline for the management of community-acquired pneumonia in adults. <i>Journal of Thoracic Disease</i> , 2017, 9, 1469-1502.	0.6	63
392	Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study. <i>Journal of Thoracic Disease</i> , 2017, 9, 1538-1546.	0.6	6
393	Achoo, achis, ATCHIN! Vaccine youâ€¦. <i>European Respiratory Journal</i> , 2018, 51, 1702558.	3.1	4
394	An Assessment of an Outpatient Antimicrobial Therapy Program in a Rural Medical Center. <i>Critical Care Nursing Quarterly</i> , 2018, 41, 109-120.	0.4	0
395	Utility of communityâ€¦acquired pneumonia severity scores in guiding disposition from the emergency department: Intensive care or shortâ€¦stay unit?. <i>EMA - Emergency Medicine Australasia</i> , 2018, 30, 538-546.	0.5	8
396	Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. <i>BMJ Open</i> , 2018, 8, e018709.	0.8	33
397	Economic and survival burden of dysphagia among inpatients in the United States. <i>Ecological Management and Restoration</i> , 2018, 31, 1-7.	0.2	133
398	Serum 25â€¦hydroxyvitamin D levels in hospitalized adults with communityâ€¦acquired pneumonia. <i>Clinical Respiratory Journal</i> , 2018, 12, 2220-2227.	0.6	11
399	Cost effectiveness of pneumococcal urinary antigen in Emergency Department: a pragmatic real-life study. <i>Internal and Emergency Medicine</i> , 2018, 13, 69-73.	1.0	9
400	Current Status of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. <i>Chinese Medical Journal</i> , 2018, 131, 1086-1091.	0.9	7
401	Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 733-752.	0.8	21
402	Pneumonia in Geriatric Patients. , 2018, , 77-87.		0
403	Early mobilisation of patients with community-acquired pneumonia reduce length of hospitalisationâ€¦a pilot study. <i>Journal of Physical Therapy Science</i> , 2018, 30, 926-932.	0.2	7
404	Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia?. <i>Annals of Emergency Medicine</i> , 2019, 74, e1-e3.	0.3	1
405	Intra-hospital mortality for community-acquired pneumonia in mainland Portugal between 2000 and 2009. <i>Pulmonology</i> , 2019, 25, 66-70.	1.0	14
406	Point of Care eGFR and the Prediction of Outcomes in Pneumonia. <i>Scientific Reports</i> , 2019, 9, 8478.	1.6	7

#	ARTICLE	IF	CITATIONS
407	Progression of the Radiologic Severity Index is associated with increased mortality and healthcare resource utilisation in acute leukaemia patients with pneumonia. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000471.	1.2	4
408	Hypothyroidism Increases 90-Day Complications and Cost Following Primary Total Hip Arthroplasty. <i>The Journal of Hip Surgery</i> , 2019, 03, 062-067.	0.1	2
409	Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign. <i>Internal and Emergency Medicine</i> , 2019, 14, 377-394.	1.0	5
412	Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa065.	0.4	13
413	Incidence, mortality, and lethality of hospitalizations for community-acquired pneumonia with comorbid cardiovascular disease in Spain (1997-2015). <i>BMC Infectious Diseases</i> , 2020, 20, 477.	1.3	10
414	The effects of smoking on adolescent trauma patients: a propensity-score-matched analysis. <i>Pediatric Surgery International</i> , 2020, 36, 743-749.	0.6	4
415	EAT-10 Scores and Fiberoptic Endoscopic Evaluation of Swallowing in Head and Neck Cancer Patients. <i>Laryngoscope</i> , 2021, 131, E45-E51.	1.1	15
418	Do meteorological changes and air pollution increase the risk of pneumonia?. <i>Tuberkuloz Ve Toraks</i> , 2021, 69, 21-29.	0.2	0
419	Comparative cost-utility analysis of postoperative discharge pathways following posterior spinal fusion for scoliosis in non-ambulatory cerebral palsy patients. <i>Spine Deformity</i> , 2021, 9, 1659-1667.	0.7	0
420	Computerized Mortality Prediction for Community-acquired Pneumonia at 117 Veterans Affairs Medical Centers. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1175-1184.	1.5	6
421	Health economics matters in the nanomaterial world: Cost-effectiveness of utilizing an inhalable antibacterial nanomaterial for the treatment of multidrug-resistant pneumonia. <i>Technology in Society</i> , 2021, 66, 101641.	4.8	4
422	Neuromuscular Blockade Monitoring and Reversal. <i>Advances in Anesthesia</i> , 2021, 39, 169-188.	0.5	0
423	Nonneoplastic Parenchymal Lung Disease. , 2009, , 863-926.		2
424	Evaluation of Antibiotic Usage With a Local Community-Acquired Pneumonia Guideline. <i>Infectious Diseases in Clinical Practice</i> , 2005, 13, 60-64.	0.1	2
425	Community-acquired Pneumonia: Compliance with Centers for Medicare and Medicaid Services, National Guidelines, and Factors Associated with Outcome. <i>Southern Medical Journal</i> , 2003, 96, 949-959.	0.3	25
426	Antimicrobial Resistance among Isolates of Respiratory Tract Infection Pathogens from the Southern United States: Data from the PROTEKT US Surveillance Program 2000/2001. <i>Southern Medical Journal</i> , 2003, 96, 974-985.	0.3	18
428	Using the Electronic Medical Record to Identify Community-Acquired Pneumonia: Toward a Replicable Automated Strategy. <i>PLoS ONE</i> , 2013, 8, e70944.	1.1	30
429	Cost-Effectiveness and Antimicrobial Resistance in Community-Acquired Pneumonia. <i>The Open Antimicrobial Agents Journal</i> , 2010, 3, 79-83.	0.2	1

#	ARTICLE	IF	CITATIONS
430	Gender differences in community-acquired pneumonia. <i>Minerva Medica</i> , 2020, 111, 153-165.	0.3	32
431	Diagnosing community-acquired pneumonia via a smartphone-based algorithm: a prospective cohort study in primary and acute-care consultations. <i>British Journal of General Practice</i> , 2021, 71, e258-e265.	0.7	13
432	Diagnostics and treatment of community-acquired pneumonia - simplicity is the key to success. <i>Vnitřní Lékarství</i> , 2017, 63, 770-775.	0.1	6
434	Disease burden of pneumonia in Korean adults aged over 50 years stratified by age and underlying diseases. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 764.	0.7	15
436	Comparison of Severity Scoring Systems in Community-Acquired Pneumonia. <i>Eurasian Journal of Pulmonology</i> , 2015, 17, 15-21.	0.2	2
437	Hospital Treatment Costs and Factors Affecting These Costs in Community-Acquired Pneumonia. <i>Turkish Thoracic Journal</i> , 2015, 16, 107-113.	0.1	6
438	Medical costs of fourteen occupational illnesses in the United States in 1999. <i>Scandinavian Journal of Work, Environment and Health</i> , 2003, 29, 304-313.	1.7	37
439	Inter-rater Agreement for the Clinical Dysphagia Scale. <i>Annals of Rehabilitation Medicine</i> , 2011, 35, 470.	0.6	15
440	Decisions about Treating Community-Acquired Pneumonia. <i>Annals of Internal Medicine</i> , 2005, 142, 215.	2.0	6
441	Toplum kâçkenli pnömoniyeye neden olan etkenler ve mortalitenin deęerlendirilmesi. <i>Pamukkale Medical Journal</i> , 0, , .	0.2	0
442	Current Issues Involved in the Treatment of Community-Acquired Pneumonia. , 2003, , 31-42.		0
443	Treatment of Hospitalized Patients with Community-Acquired Pneumonia. , 2003, , 279-306.		0
444	Cost Considerations in the Use of Antibiotics for the Treatment of Community-Acquired Respiratory Tract Infections. , 2003, , 59-74.		0
445	Cost Considerations in the Use of Antibiotics for the Treatment of Community-Acquired Respiratory Tract Infections. , 2003, , 43-58.		0
446	Treatment of Pneumonia in Nonhospitalized Patients. , 2003, , 255-278.		0
447	Pneumonia: How Did We Evolve? (Colombian Vision). , 2004, , 15-21.		0
448	IN THE ELDERLY. <i>The Consultant Pharmacist</i> , 2004, 19, 195-213.	0.4	3
449	Pulmonary Infections: Imaging with MDCT. <i>Medical Radiology</i> , 2006, , 107-120.	0.0	1

#	ARTICLE	IF	CITATIONS
450	Management of community-acquired pneumonia. , 2006, , 353-370.		0
451	Community-Acquired Respiratory Complications in the Intensive Care Unit: Pneumonia and Acute Exacerbations of COPD. , 2007, , 435-448.		0
453	Cambios del esquema antibi3tico en neumon3a adquirida en la comunidad. Valor del cultivo de esputo en pacientes ingresados al Hospital de San Jos3, Bogot3; D.C.. Repertorio De Medicina Y Cirugia, 2009, 18, 36-46.	0.0	0
458	Chapter 13. Drug Discovery for Lower Respiratory Tract Infections. RSC Drug Discovery Series, 2011, , 366-411.	0.2	1
459	Comparing therapeutic and adverse effects of moxifloxacin and levofloxacin in treatment of community acquired pneumonia: A meta- analysis of randomized controlled trials. African Journal of Microbiology Research, 2012, 6, .	0.4	0
460	Validation of a Risk-Based Biomarker-Enhanced Scoring System for Lower Respiratory Tract Infections (OPTIMA I Basel)3An Observational Survey. International Journal of Clinical Medicine, 2013, 04, 69-77.	0.1	0
461	LUNG INFECTIONS AND TUBERCULOSIS. Toraks Cerrahisi Bulteni, 2013, 4, 163-170.	0.0	0
462	Use of preparation Levostad (levofloxacin) at patients with the chronic prostatitis. Health of Man, 2015, .	0.1	1
463	Pneumonia in Geriatric Patients. , 2017, , 1-11.		0
464	Medizinische Folgen von Dysphagien. , 2018, , 135-146.		0
466	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. Therapy: Open Access in Clinical Medicine, 2005, 2, 357-373.	0.2	0
467	Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. Cmaj, 2000, 162, 1415-20.	0.9	16
468	Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. Therapeutics and Clinical Risk Management, 2006, 2, 59-75.	0.9	2
469	BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax, 2001, 56 Suppl 4, IV1-64.	2.7	154
471	Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clinical Infectious Diseases, 2008, 47 Suppl 3, S249-65.	2.9	20
472	Alcoholic lung disease. Alcohol Research, 2008, 31, 66-75.	1.0	25
473	The incidence rate and economic burden of community-acquired pneumonia in a working-age population. American Health and Drug Benefits, 2013, 6, 494-503.	0.5	49
474	Ambulant erworbene Pneumonie: Wie antibiotisch therapieren?. , 0, , .		0

#	ARTICLE	IF	CITATIONS
475	Morbilidade e Mortalidade da Pneumonia Adquirida na Comunidade no Adulto, em Portugal. Acta Medica Portuguesa, 2013, 26, 644-645.	0.2	7
480	Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital. Scientific Reports, 2022, 12, .	1.6	11
482	Effects of Juhongtanke oral solution on alleviating the symptoms of community-acquired pneumonia: A multicenter, prospective, randomized controlled trial. Frontiers in Pharmacology, 0, 13, .	1.6	0
483	Short treatment duration for community-acquired pneumonia. Current Opinion in Infectious Diseases, 0, Publish Ahead of Print, .	1.3	0
484	Videofluoroscopy dysphagia severity scale is predictive of subsequent remote pneumonia in dysphagia patients. International Journal of Medical Sciences, 2023, 20, 429-436.	1.1	3
488	Medizinische Folgen von Dysphagien. , 2024, , 157-170.		0